Trial Profile
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs IMF 001 (Primary) ; Poly ICLC (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions; Expanded access
- 18 May 2012 New trial record